The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke

Mitchell S V Elkind, Ralph L Sacco, Robert B. Macarthur, Daniel J. Fink, Ellinor Peerschke, Howard Andrews, Greg Neils, Josh Stillman, Tania Corporan, Dana Leifer, Ken Cheung

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

There is growing experimental and clinical evidence that by reducing downstream products of the mevalonate pathway other than cholesterol, HMG-CoA reductase inhibitors ('statins') have beneficial effects on endothelial function, coronary and cerebral blood flow, inflammation, and hemostasis. Statins have been shown in rodent models of acute ischemic stroke to reduce neuronal injury and infarct size in a dose-dependent fashion. The objective of this early phase trial will be to determine the maximal-tolerated dose of lovastatin for short-term acute stroke therapy. In this multicenter phase 1B dose-escalation and dose-finding study, 33 patients with acute ischemic stroke will be administered lovastatin in increasing doses from one to 10 mg/kg daily for 3 days beginning within 24 hours after symptom onset. The primary safety outcome will be occurrence of myotoxicity or hepatotoxicity, defined by clinical and laboratory criteria, and the study is designed to determine the highest dose of lovastatin that can be administered with <10% risk of myotoxicity or hepatotoxicity. The statistical design of the study utilizes an adaptive design, the Continual Reassessment Method, which is novel to stroke trials, to find the optimal dosage. The dose-toxicity model is calibrated such that the method will eventually select a dose that causes 7-13% dose-limiting toxicity (within 3% of target). A sample size of 33 will ensure that estimates of any binary variables will have a 95% confidence interval of width ≤0.34, and enable us to detect any unexpected toxicity that occurs at 5% rate (in a non-dose-dependent fashion) with probability 0.82. The probability of choosing a dose for further trials with 25% or higher likelihood of toxicity is no more than 23%. The presently described trial represents a new approach for treatment of acute ischemic stroke, as well as a novel way of conducting a phase I trial, evaluating safety and determining an optimal dose of a potential neuroprotectant drug.

Original languageEnglish
Pages (from-to)210-218
Number of pages9
JournalInternational Journal of Stroke
Volume3
Issue number3
DOIs
StatePublished - Aug 12 2008

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lovastatin
Stroke
Cerebrovascular Circulation
Therapeutics
Safety
Mevalonic Acid
Maximum Tolerated Dose
Neuroprotective Agents
Hemostasis
Sample Size
Rodentia
Cholesterol
Neuroprotection
Confidence Intervals
Inflammation
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Clinical trial
  • Neuroprotection
  • Statins
  • Stroke

ASJC Scopus subject areas

  • Neurology

Cite this

The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART) : An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. / Elkind, Mitchell S V; Sacco, Ralph L; Macarthur, Robert B.; Fink, Daniel J.; Peerschke, Ellinor; Andrews, Howard; Neils, Greg; Stillman, Josh; Corporan, Tania; Leifer, Dana; Cheung, Ken.

In: International Journal of Stroke, Vol. 3, No. 3, 12.08.2008, p. 210-218.

Research output: Contribution to journalArticle

Elkind, Mitchell S V ; Sacco, Ralph L ; Macarthur, Robert B. ; Fink, Daniel J. ; Peerschke, Ellinor ; Andrews, Howard ; Neils, Greg ; Stillman, Josh ; Corporan, Tania ; Leifer, Dana ; Cheung, Ken. / The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART) : An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. In: International Journal of Stroke. 2008 ; Vol. 3, No. 3. pp. 210-218.
@article{1cc826052726417d915e197b753f96fd,
title = "The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke",
abstract = "There is growing experimental and clinical evidence that by reducing downstream products of the mevalonate pathway other than cholesterol, HMG-CoA reductase inhibitors ('statins') have beneficial effects on endothelial function, coronary and cerebral blood flow, inflammation, and hemostasis. Statins have been shown in rodent models of acute ischemic stroke to reduce neuronal injury and infarct size in a dose-dependent fashion. The objective of this early phase trial will be to determine the maximal-tolerated dose of lovastatin for short-term acute stroke therapy. In this multicenter phase 1B dose-escalation and dose-finding study, 33 patients with acute ischemic stroke will be administered lovastatin in increasing doses from one to 10 mg/kg daily for 3 days beginning within 24 hours after symptom onset. The primary safety outcome will be occurrence of myotoxicity or hepatotoxicity, defined by clinical and laboratory criteria, and the study is designed to determine the highest dose of lovastatin that can be administered with <10{\%} risk of myotoxicity or hepatotoxicity. The statistical design of the study utilizes an adaptive design, the Continual Reassessment Method, which is novel to stroke trials, to find the optimal dosage. The dose-toxicity model is calibrated such that the method will eventually select a dose that causes 7-13{\%} dose-limiting toxicity (within 3{\%} of target). A sample size of 33 will ensure that estimates of any binary variables will have a 95{\%} confidence interval of width ≤0.34, and enable us to detect any unexpected toxicity that occurs at 5{\%} rate (in a non-dose-dependent fashion) with probability 0.82. The probability of choosing a dose for further trials with 25{\%} or higher likelihood of toxicity is no more than 23{\%}. The presently described trial represents a new approach for treatment of acute ischemic stroke, as well as a novel way of conducting a phase I trial, evaluating safety and determining an optimal dose of a potential neuroprotectant drug.",
keywords = "Clinical trial, Neuroprotection, Statins, Stroke",
author = "Elkind, {Mitchell S V} and Sacco, {Ralph L} and Macarthur, {Robert B.} and Fink, {Daniel J.} and Ellinor Peerschke and Howard Andrews and Greg Neils and Josh Stillman and Tania Corporan and Dana Leifer and Ken Cheung",
year = "2008",
month = "8",
day = "12",
doi = "10.1111/j.1747-4949.2008.00200.x",
language = "English",
volume = "3",
pages = "210--218",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART)

T2 - An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke

AU - Elkind, Mitchell S V

AU - Sacco, Ralph L

AU - Macarthur, Robert B.

AU - Fink, Daniel J.

AU - Peerschke, Ellinor

AU - Andrews, Howard

AU - Neils, Greg

AU - Stillman, Josh

AU - Corporan, Tania

AU - Leifer, Dana

AU - Cheung, Ken

PY - 2008/8/12

Y1 - 2008/8/12

N2 - There is growing experimental and clinical evidence that by reducing downstream products of the mevalonate pathway other than cholesterol, HMG-CoA reductase inhibitors ('statins') have beneficial effects on endothelial function, coronary and cerebral blood flow, inflammation, and hemostasis. Statins have been shown in rodent models of acute ischemic stroke to reduce neuronal injury and infarct size in a dose-dependent fashion. The objective of this early phase trial will be to determine the maximal-tolerated dose of lovastatin for short-term acute stroke therapy. In this multicenter phase 1B dose-escalation and dose-finding study, 33 patients with acute ischemic stroke will be administered lovastatin in increasing doses from one to 10 mg/kg daily for 3 days beginning within 24 hours after symptom onset. The primary safety outcome will be occurrence of myotoxicity or hepatotoxicity, defined by clinical and laboratory criteria, and the study is designed to determine the highest dose of lovastatin that can be administered with <10% risk of myotoxicity or hepatotoxicity. The statistical design of the study utilizes an adaptive design, the Continual Reassessment Method, which is novel to stroke trials, to find the optimal dosage. The dose-toxicity model is calibrated such that the method will eventually select a dose that causes 7-13% dose-limiting toxicity (within 3% of target). A sample size of 33 will ensure that estimates of any binary variables will have a 95% confidence interval of width ≤0.34, and enable us to detect any unexpected toxicity that occurs at 5% rate (in a non-dose-dependent fashion) with probability 0.82. The probability of choosing a dose for further trials with 25% or higher likelihood of toxicity is no more than 23%. The presently described trial represents a new approach for treatment of acute ischemic stroke, as well as a novel way of conducting a phase I trial, evaluating safety and determining an optimal dose of a potential neuroprotectant drug.

AB - There is growing experimental and clinical evidence that by reducing downstream products of the mevalonate pathway other than cholesterol, HMG-CoA reductase inhibitors ('statins') have beneficial effects on endothelial function, coronary and cerebral blood flow, inflammation, and hemostasis. Statins have been shown in rodent models of acute ischemic stroke to reduce neuronal injury and infarct size in a dose-dependent fashion. The objective of this early phase trial will be to determine the maximal-tolerated dose of lovastatin for short-term acute stroke therapy. In this multicenter phase 1B dose-escalation and dose-finding study, 33 patients with acute ischemic stroke will be administered lovastatin in increasing doses from one to 10 mg/kg daily for 3 days beginning within 24 hours after symptom onset. The primary safety outcome will be occurrence of myotoxicity or hepatotoxicity, defined by clinical and laboratory criteria, and the study is designed to determine the highest dose of lovastatin that can be administered with <10% risk of myotoxicity or hepatotoxicity. The statistical design of the study utilizes an adaptive design, the Continual Reassessment Method, which is novel to stroke trials, to find the optimal dosage. The dose-toxicity model is calibrated such that the method will eventually select a dose that causes 7-13% dose-limiting toxicity (within 3% of target). A sample size of 33 will ensure that estimates of any binary variables will have a 95% confidence interval of width ≤0.34, and enable us to detect any unexpected toxicity that occurs at 5% rate (in a non-dose-dependent fashion) with probability 0.82. The probability of choosing a dose for further trials with 25% or higher likelihood of toxicity is no more than 23%. The presently described trial represents a new approach for treatment of acute ischemic stroke, as well as a novel way of conducting a phase I trial, evaluating safety and determining an optimal dose of a potential neuroprotectant drug.

KW - Clinical trial

KW - Neuroprotection

KW - Statins

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=48849116060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849116060&partnerID=8YFLogxK

U2 - 10.1111/j.1747-4949.2008.00200.x

DO - 10.1111/j.1747-4949.2008.00200.x

M3 - Article

C2 - 18705902

AN - SCOPUS:48849116060

VL - 3

SP - 210

EP - 218

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 3

ER -